THE first diagnostic test for long COVID is now available to patients across Australia.
The test can help physicians diagnose long COVID by differentiating it from other diseases with similar symptoms, which will enable them to design personalised treatment approaches.
The simple blood-based test was developed by diagnostic testing company IGeneX using IncellDx's incellKINE assay.
IncellKINE is a machine learning-based technology that is able to assess the presence of a distinctive immunologic profile characterised by patterns of cytokine and chemokine biomarkers found to be unique to long COVID patients, as reported in Frontiers in Immunology.
The long COVID test provides 97% sensitivity.
To learn more and to book a test CLICK HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 May 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 May 23
